The BBB penetrating drugs market is projected to grow at an annualized rate of ~154%, till 2030
Roots Analysis has done a detailedstudy on Blood-Brain Barrier (BBB) Market (2ndEdition), 2020-2030: Focus on Non-Invasive Drug Delivery TechnologyPlatforms and Therapeutics, covering key aspects of the industry’sevolution and identifying potential future growth opportunities.
To order this 400+ page report, which features 145+ figuresand 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html
Key Market Insights
§ More than 110 drugs,capable of penetrating this elusive barrier are currently being evaluated forthe treatment of CNS disorders; there are 35+ technology platforms for thedevelopment of BBB penetrant drugs
§ Majority of drugcandidates are currently in the early stages of development, and are intendedfor the treatment of neurological conditions; a large proportion of theexisting pipeline molecules are biologics
§ In order to achieve acompetitive edge, several technology developers are presently focusing on theintegration of advanced technical features into their proprietary drugdevelopment / delivery platforms
§ An assessment of 240+drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed thatmany such firms are likely to partner with technology providers in order toleverage their BBB penetration expertise
§ Over the years, morethan 16,700 patents related to BBB technologies have been filed / granted tovarious industry and non-industry players, indicating the pace of R&Dactivity in this burgeoning field of research
§ Foreseeing alucrative future, several private and public investors have invested close toUSD 1 billion, across more than 70 funding instances
§ Revenues generatedfrom the sales of BBB penetrating drugs are anticipated to be well distributedacross different types of molecules, target disease indications and variousglobal regions over time
§ In the near-term, theopportunity is likely to be driven by licensing activity driven by thecapability of leading BBB penetrating technologies to successfully facilitatedrug delivery into the brain
For more information, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of theHuman Brain
3.3. Global Burden onNeurological Disorders and Impact of Coronavirus Disease (COVID-19)
3.4. Strategies forDrug Delivery to the Central Nervous System (CNS)
3.4.1. InvasiveTechniques
3.4.1.1. SystemicAdministration of Therapeutics
3.4.1.2. DirectAdministration of Therapeutics
3.4.1.3.Intracerebral Devices and Implants
3.4.2. Non-InvasiveTechniques / Approaches
3.4.2.1. Liposomes
3.4.2.2. Exosomes
3.4.2.3. Prodrugs
3.4.2.4.Nanoparticles and Microspheres
3.4.2.5. NovelFormulations and Conjugates
3.4.3. ChemicalDelivery Systems
3.5. Blood-BrainBarrier (BBB)
3.5.1. Key HistoricalMilestones
3.5.2. Structure andKey Components
3.5.3. Key Functions
3.6. Strategies forDrug Delivery across the BBB
3.6.1. IncreasingPermeability by Temporary Disruption of the BBB
3.6.2.Pharmacological Strategies to Facilitate Transport Across the BBB
3.7. ChallengesAssociated with BBB Penetration and CNS Drug Delivery
3.8. Prevalent TrendsRelated to Non-Invasive BBB Penetration Technologies
3.8.1. Emerging FocusAreas
3.8.2. Key HistoricalTrends
3.8.3. GeographicalActivity
3.9. ConcludingRemarks
4. MARKET LANDSCAPE:NON-INVASIVE BBB PENETRATION
4.1. Chapter Overview
4.2. Non-Invasive BBBPenetration Technologies: Overall Market Landscape
4.2.1. Analysis byStatus of Development
4.2.2. Analysis byUnderlying Principle
4.2.3. Analysis byCompatible Pharmacological Molecule(s)
4.2.4. Analysis byTarget Receptor(s)
4.2.5. Analysis byTarget Disease Indication(s)
4.2.6. Analysis byPatent Availability
4.2.7. Analysis byLicensing Activity
4.3. Non-Invasive BBBPenetration Technology Providers: Overall Market Landscape
4.3.1. Analysis byYear of Establishment
4.3.2. Analysis byCompany Size
4.3.3. Analysis byLocation of Headquarters
5. MARKET LANDSCAPE:BBB PENETRATING DRUGS
5.1. Chapter Overview
5.2. BBB PenetratingDrugs: Development Pipeline
5.2.1. Analysis byPhase of Development
5.2.2. Analysis byType of Molecule
5.2.3. Analysis byAffiliated BBB Penetration Technology
5.2.4. Analysis byRoute of Administration
5.2.5. Analysis byTarget Disease Indication(s)
5.2.6. Analysis byTherapeutic Area(s)
5.3. BBB PenetratingDrugs: Additional Information
5.4. BBB PenetratingDrug Developers: Overall Market Landscape
5.4.1. Analysis byYear of Establishment
5.4.2. Analysis byCompany Size
5.4.3. Analysis byLocation of Headquarters
5.4.4. Leading DrugDevelopers: Analysis by Number of Drugs
5.4.5. Leading DrugDevelopers: 4D Bubble Analysis based on Pipeline Strength, Target DiseaseIndication and Company Size
5.4.6. HeptagonRepresentation: Analysis by Phase of Development and Key Disease Indications
5.4.7. Tree MapRepresentation: Analysis by Key Disease Indications and Size of the Company
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Playersbased in North America
6.2.1. Angiochem
6.2.1.1. CompanyOverview
6.2.1.2. TechnologyOverview
6.2.1.3. ProductPortfolio
6.2.1.4. RecentDevelopments and Future Outlook
6.2.2. ArmaGen
6.2.2.1. CompanyOverview
6.2.2.2. TechnologyOverview
6.2.2.3. ProductPortfolio
6.2.2.4. RecentDevelopments and Future Outlook
6.2.3. DenaliTherapeutics
6.2.3.1. CompanyOverview
6.2.3.2. TechnologyOverview
6.2.3.3. ProductPortfolio
6.2.3.4. RecentDevelopments and Future Outlook
6.2.4. ICBInternational
6.2.4.1. CompanyOverview
6.2.4.2. TechnologyOverview
6.5.4.3. ProductPortfolio
6.2.4.4. RecentDevelopments and Future Outlook
6.2.5. LaurenSciences
6.2.5.1. CompanyOverview
6.2.5.2. TechnologyOverview
6.2.5.3. ProductPortfolio
6.2.5.4. Recent Developmentsand Future Outlook
6.3. Leading Playersbased in Europe
6.3.1. BioArctic
6.3.1.1. CompanyOverview
6.3.1.2. TechnologyOverview
6.3.1.3. ProductPortfolio
6.3.1.4. RecentDevelopments and Future Outlook
6.3.2. CycleniumPharma
6.3.2.1. CompanyOverview
6.3.2.2. TechnologyOverview
6.3.2.3. ProductPortfolio
6.3.2.4. RecentDevelopments and Future Outlook
6.3.3. Iproteos
6.3.3.1. CompanyOverview
6.3.3.2. TechnologyOverview
6.3.3.3. ProductPortfolio
6.3.3.4. RecentDevelopments and Future Outlook
6.3.4. Medesis Pharma
6.3.4.1. CompanyOverview
6.3.4.2. TechnologyOverview
6.3.4.3. ProductPortfolio
6.3.4.4. RecentDevelopments and Future Outlook
6.3.5. Ossianix
6.3.5.1. CompanyOverview
6.3.5.2. TechnologyOverview
6.3.5.3. ProductPortfolio
6.3.5.4. RecentDevelopments and Future Outlook
6.3.6. Vect-Horus
6.3.6.1. CompanyOverview
6.3.6.2. TechnologyOverview
6.3.6.3. ProductPortfolio
6.3.6.4. RecentDevelopments and Future Outlook
6.4. Leading Playersbased in Asia-Pacific
6.4.1. JCRPharmaceuticals
6.4.1.1. CompanyOverview
6.4.1.2. TechnologyOverview
6.4.1.3. ProductPortfolio
6.4.1.4. RecentDevelopments and Future Outlook
7. TECHNOLOGYCOMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology andKey Parameters
7.3. BBB PenetrationTechnologies: Platform Competitiveness Analysis
8. NON-INVASIVE BBBPENETRATION TECHNOLOGIES: POPULAR APPROACHES
8.1. Chapter overview
8.2. ReceptorMediated Transcytosis (RMT)
8.2.1. Type of TargetReceptors
8.2.1.1. DiphtheriaToxin Receptor
8.2.1.2. InsulinReceptor and Insulin-like Growth Factor Receptor
8.2.1.3. Low DensityLipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)
8.2.1.4. TransferrinReceptor
8.2.2. Types of RMTApproaches
8.2.2.1. Bispecific Antibody-basedApproach
8.2.2.2. MolecularTrojan Horse-based Approach
8.2.2.2.1. ImportantConsiderations for Designing Molecular Trojan Horses
8.2.2.2.2.Considerations for Designing a Trojan Horse Liposome (THL)
8.2.2.2.3. PopularConjugation Strategies
8.2.2.2.3.1. DirectCoupling Approach
8.2.2.2.3.2.Nanoparticles-based Approach
8.3. Increasing thePermeability of the BBB
8.3.1. Use ofUltrasound Waves
8.3.2. Use ofHigh-Frequency Electric Field
8.4. PassiveDiffusion
8.5. Novel Approaches
8.5.1. CellPenetrating Peptides
8.5.2. Macrocycles
8.5.3.Organ-on-a-Chip Technology
9. PARTNERSHIPS ANDCOLLABORATIONS
9.1. Chapter Overview
9.2. PartnershipModels
9.3. Non-Invasive BBBTechnologies and Drugs: List of Partnerships and Collaborations
9.3.1. Analysis byYear of Partnership
9.3.2. Analysis byType of Partnership
9.3.3. Analysis byYear and Type of Partnership
9.3.4. Analysis byType of Partner
9.3.5. Analysis byFocus Area
9.3.6. Analysis byType of Molecule
9.3.7. Analysis byTarget Disease Indication
9.3.8. Most ActivePlayers: Analysis by Number of Partnerships
9.3.9. Most PopularTechnologies: Analysis by Number of Partnerships
9.3.10. RegionalAnalysis
9.3.11.Intercontinental and Intracontinental Agreements
10. ANALYSIS OFRECENT LICENSING AGREEMENTS
10.1. ChapterOverview
10.2. LicensingAgreements: Definition and Importance in Pharmaceutical Industry
10.3. Types ofLicensing Agreements
10.3.1. Out-LicensingAgreements
10.3.2. In-LicensingAgreements
10.4. Components ofLicensing Agreements
10.5. Recent Examplesof BBB-Related Technology Licensing Agreements
10.5.1. Analysis byYear of Agreement
10.5.2. Analysis byType of Licensing Agreement
10.5.3. Analysis byType of Owner
10.5.4. Most ActivePlayers: Analysis by Number of Licensing Agreements
10.5.5. Most PopularTechnologies: Analysis by Number of Licensing Agreements
10.5.6. RegionalAnalysis
10.5.7.Intercontinental and Intracontinental Licensing Agreements
10.6. Case-in-Point:Technology Licensing Timeline
10.6.1. SumitomoDainippon Pharma and JCR Pharmaceuticals
10.6.2. DenaliTherapeutics and Sanofi
10.6.3. biOasisTechnologies and Prothena
10.6.4. Vect-Horusand Janssen Pharmaceuticals
10.7. ConcludingRemarks
11. FUNDING ANDINVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types ofFunding
11.3. Non-InvasiveBBB Penetration Technologies and Drugs: List of Funding and Investments
11.3.1. Analysis byNumber of Instances
11.3.2. Analysis byAmount Invested
11.3.3. Analysis byType of Funding
11.3.4. Analysis byType of Company
11.3.5. Analysis byPurpose of Funding
11.3.6. Analysis byType of Molecule
11.3.7. Analysis byTarget Disease Indication
11.3.8. Analysis byGeography
11.3.9. Most ActivePlayers: Analysis by Number of Funding Instances
11.3.10. Most PopularTechnologies: Analysis by Number of Funding Instances
11.3.11. Most ActiveInvestors: Analysis by Number of Funding Instances
11.4. ConcludingRemarks
12. PATENT ANALYSIS
12.1. ChapterOverview
12.2. Scope andMethodology
12.3. Non-InvasiveBBB Penetration Technologies: Patent Analysis
12.3.1. Analysis byApplication Year
12.3.1.1. Analysis byFiled Patent Applications
12.3.1.2. Analysis byGranted Patent Applications
12.3.2. Analysis byIssuing Authority / Patent Offices Involved
12.3.3. Analysis byCPC Symbols
12.3.4. EmergingFocus Areas
12.3.5. Analysis byType of Organization
12.3.6. LeadingAssignees: Analysis by Number of Patents
12.4. Non-InvasiveBBB Technologies: Patent Valuation Analysis
13. DRUG DEVELOPMENTSTRATEGY ANALYSIS
13.1. ChapterOverview
13.2 Scope andMethodology
13.3. StrategiesAdopted by Late-Stage Drug Candidates
13.3.1. Drug A
13.3.2. Drug B
13.3.3. Drug C
13.3.4. Drug D
13.4. ConcludingRemarks
14. MARKET POTENTIALOF KEY NEUROLOGICAL DISORDERS
14.1. ChapterOverview
14.2. MarketPotential of Key Neurological Disorders: 3D Bubble Chart Analysis
14.3. KeyNeurological Disorders: Detailed Information
14.3.1. Alzheimer’sDisease
14.3.1.1. DiseaseDescription
14.3.1.2.Epidemiology
14.3.1.3. Symptoms
14.3.1.4. CurrentTreatment Options
14.3.1.5. BBBPenetrating Drugs for Alzheimer’s Disease
14.3.1.6. RootsAnalysis Perspective
14.3.2. Brain Cancer
14.3.2.1. DiseaseDescription
14.3.2.2.Epidemiology
14.3.2.3. Symptoms
14.3.2.4. CurrentTreatment Options
14.3.2.4.1. Surgery
14.3.2.4.2. RadiationTherapy
14.3.2.4.3. SystemicTherapy
14.3.2.5. BBBPenetrating Drugs for Brain Cancer
14.3.2.6. RootsAnalysis Perspective
14.3.3. MultipleSclerosis
14.3.3.1. DiseaseDescription
14.3.3.2.Epidemiology
14.3.3.3. Symptoms
14.3.3.4. CurrentTreatment Options
14.3.3.4.1. Treatmentfor Attacks
14.3.3.4.2.Treatments to Modify Progression
14.3.3.4.3.Interferons
14.3.3.5. BBBPenetrating Drugs for Multiple Sclerosis
14.3.3.6. RootsAnalysis Perspective
14.3.4. Parkinson’sDisease
14.3.4.1. DiseaseDescription
14.3.4.2.Epidemiology
14.3.4.3. Symptoms
14.3.4.4. CurrentTreatment Options
14.3.4.4.1.Pharmacological Management of Parkinson’s Disease
14.3.4.4.2.Non-Pharmacological Management of Parkinson’s Disease
14.3.4.4.3.Management of Parkinson’s Disease using Dietary Supplements
14.3.4.5. BBBPenetrating Drugs for Parkinson’s Disease
14.3.4.6. RootsAnalysis Perspective
15. LIKELY PARTNERANALYSIS
15.1. ChapterOverview
15.2. Scope andMethodology
15.3. PotentialStrategic Partners for Drug Development
15.3.1. Opportunitiesin North America
15.3.1.1. Most LikelyPartners
15.3.1.2. LikelyPartners
15.3.1.3. Less LikelyPartners
15.3.2. Opportunitiesin Europe
15.3.2.1. Most LikelyPartners
15.3.2.2. LikelyPartners
15.3.2.3. Less LikelyPartners
15.3.3. Opportunitiesin Asia-Pacific and Rest of the World
15.3.3.1. Most LikelyPartners
15.3.3.2. LikelyPartners
15.3.3.3. Less LikelyPartners
16. MARKET FORECAST
16.1. ChapterOverview
16.2. ForecastMethodology and Key Assumptions
16.3. Overall BBBPenetration Technologies Market, 2020-2030
16.3.1. BBBPenetration Technologies Market: Contribution from Upfront Payments, 2020-2030
16.3.2. BBBPenetration Technologies Contribution from Milestone Payments, 2020-2030
16.4. Overall BBBPenetrating Drugs Market, 2020-2030
16.4.1. BBBPenetrating Drugs Market: Distribution by Type of Molecule
16.4.1.1. BBBPenetrating Drugs Market for Small Molecules, 2020-2030
16.4.1.2. BBBPenetrating Drugs Market for Biologics, 2020-2030
16.4.2. BBBPenetrating Drugs Market: Distribution by Target Disease Indication
16.4.2.1. BBBPenetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030
16.4.2.2. BBBPenetrating Drugs Market for Glioblastoma Multiforme, 2020-2030
16.4.2.3. BBBPenetrating Drugs Market for Hunter Syndrome, 2020-2030
16.4.2.4. BBBPenetrating Drugs Market for Hurler Syndrome, 2020-2030
16.4.3. BBBPenetrating Drugs Market: Distribution by Key Geographical Regions
16.4.3.1. BBB PenetratingDrugs Market in North America, 2020-2030
16.4.3.2. BBBPenetrating Drugs Market in Europe, 2020-2030
16.4.3.3. BBBPenetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030
16.4.4. BBBPenetrating Drugs Market: Distribution by Leading Technology Platforms
16.4.5. BBBPenetrating Drugs Market: Distribution by Leading Drug Developers
16.5.6. Drug-wiseSales Forecast
16.5.6.1. 2B3-101 /2X-111 (2X Oncology)
16.5.6.1.1. SalesForecast (USD Million)
16.5.6.1.2.Risk-Adjusted Market Opportunity (USD Million)
16.5.6.1.3. NetPresent Value (USD Million)
16.5.6.1.4. ValueCreation Analysis
16.5.6.2. AGT-181(ArmaGen)
16.5.6.2.1. SalesForecast (USD Million)
16.5.6.2.2.Risk-Adjusted Market Opportunity (USD Million)
16.5.6.2.3. Net PresentValue (USD Million)
16.5.6.2.4. ValueCreation Analysis
16.5.6.3. AGT-182(ArmaGen)
16.5.6.3.1. SalesForecast (USD Million)
16.5.6.3.2.Risk-Adjusted Market Opportunity (USD Million)
16.5.6.3.3. NetPresent Value (USD Million)
16.5.6.3.4. ValueCreation Analysis
16.5.6.4. ANG1005(Angiochem)
16.5.6.4.1. SalesForecast (USD Million)
16.5.6.4.2.Risk-Adjusted Market Opportunity (USD Million)
16.5.6.4.3. NetPresent Value (USD Million)
16.5.6.4.4. ValueCreation Analysis
16.5.6.5. JR-141 (JCRPharmaceuticals)
16.5.6.5.1. SalesForecast (USD Million)
16.5.6.5.2.Risk-Adjusted Market Opportunity (USD Million)
16.5.6.5.3. NetPresent Value (USD Million)
16.5.6.5.4. ValueCreation Analysis
17. CONCLUSION
17.1. ChapterOverview
17.2. Key Takeaways
18. EXECUTIVEINSIGHTS
18.1. ChapterOverview
18.2. InnovativeCalifornia Biosciences International (ICBI)
18.2.1. CompanySnapshot
18.2.2. InterviewTranscript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
18.3. Ossianix
18.3.1. Company Snapshot
18.3.2. InterviewTranscript: Frank S Walsh, Chief Executive Officer and Founder
18.4. 2-BBB
18.4.1. CompanySnapshot
18.4.2. InterviewTranscript: Pieter Gaillard, Chief Executive Officer and Co-Founder
18.5. ArmaGen
18.5.1. Company Snapshot
18.5.2. InterviewTranscript: Mathias Schmidt, Chief Executive Officer
18.6. biOasisTechnologies
18.6.1. CompanySnapshot
18.6.2. InterviewTranscript: Rob Hutchison, Chief Executive Officer
18.7. CycleniumPharma
18.7.1. CompanySnapshot
18.7.2. InterviewTranscript: Mark L Peterson, Chief Operating Officer
18.8. Sagetis Biotech
18.8.1. CompanySnapshot
18.8.2. InterviewTranscript: Xavier Rivero, Chief Operating Officer
18.9. CarThera
18.9.1. CompanySnapshot
18.9.2. InterviewTranscript: Carole Desseaux, Head of Clinical Affairs
18.10. Vect-Horus
18.10.1. CompanySnapshot
18.10.2. InterviewTranscript: Jamal Temsamani, Head of Drug Development
18.11. WyssInstitute, Harvard University
18.11.1. OrganizationSnapshot
18.11.2. InterviewTranscript: Kevin Kit Parker, Professor
19. APPENDIX I:TABULATED DATA
20. APPENDIX II: LISTOF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
